13.1 C
Delhi
Tuesday, November 30, 2021

Covid-19 Vaccine: You will not get the option to choose between either the vaccine Covishield and Covaxin

The person receiving the vaccine will not have the option to choose from two recently approved vaccines for emergency use in India.

Covid-19 Vaccine Update: The government indicated on Tuesday that the person receiving the COVID-19 vaccine would not have the option to choose from two recently approved vaccines for emergency use in India. Responding to a question at the press conference, Union Health Secretary Rajesh Bhushan said that more than one vaccine is being installed in many places in the world, but currently, in any country, the person receiving the vaccine has to choose the shot. Is not an option.

There will be a difference of 28 days between two doses

India has recently approved two vaccines for emergency use – Oxford University’s Covishield and Bharat Biotech’s Covaxine. Bhushan said that there will be a difference of 28 days between the two doses of the COVID-19 vaccine and its effect can be seen only after 14 days. He said, therefore, he appealed to the people to follow COVID-19’s appropriate behaviour.

India will start its COVID-19 vaccination campaign from January 16. In this, about 30 million healthcare workers and frontline workers will be given priority. Bhushan said that out of the entire stock of COVID-19 vaccine doses ordered so far, 54.72 lakhs have reached the scheduled national and state level vaccine stores by Tuesday afternoon. The coronavirus vaccination campaign is going to start from Saturday.

He said that all orders – 1.1 million doses of Kovishield from Serum Institute of India and 55 lakh doses of Kovaxin from Bharat Biotech will reach by 14 January.

India Biotech orders 55 lakh doses of Covaxin, will give 16.50 lakh doses for free to the government

Four new COVID-19 vaccines to come

The Health Ministry also said on Tuesday that four more COVID-19 vaccines are under watch and manufacturers may approach the drug controller for emergency use authorization. Addressing the press conference, Rajesh Bhushan said that Zydus Cadila, Sputnik V, Biological E and Genova are the other vaccines that are in the pipeline. They are in an advanced clinical trial in India.

Business Khabar
We aim to constantly bring to you all the latest and most updated industry news across all major categories. With a wide variety of topics and categories under our umbrella, we bring to you the latest news and activities in the top sought areas of public interest.
Latest news
- Advertisement -
Related news
- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here